The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $265.69

Today's change0.00 0.00%
Updated May 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $265.69

Today's change0.00 0.00%
Updated May 21 4:00 PM EDT. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc closed at (U.S.)$265.69.

Shares have lost 13.48% over the last five days, but have gained 70.31% over the last year to date. This security has outperformed the S&P 500 by 9.05% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $265.69
  • High--
  • Low--
  • Bid / Ask(U.S.) $260.50 / (U.S.) $269.57
  • YTD % change+70.31%
  • Volume0
  • Average volume (10-day)841,332
  • Average volume (1-month)616,007
  • Average volume (3-month)639,753
  • 52-week range(U.S.) $128.50 to (U.S.) $349.08
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.58
Updated May 21 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-2,753.17%

Intercept Pharmaceuticals Inc has a net profit margin of -2,753.17%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.87%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue1000
Total other revenue--------
Total revenue1000
Gross profit--------
Total cost of revenue--------
Total operating expense41363723
Selling / general / administrative131298
Research & development28242715
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-40-35-36-22
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-39-35-3633
Income after tax-39-35-3633
Income tax, total------0
Net income-39-35-3633
Total adjustments to net income--------
Net income before extra. items-39-35-3633
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-39-35-3633
Inc. avail. to common incl. extra. items-39-35-3633
Diluted net income-39-35-3633
Dilution adjustment--------
Diluted weighted average shares22212122
Diluted EPS excluding extraordinary itemsvalue per share-1.78-1.63-1.691.51
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-1.78-1.63-1.691.51